Therefore, besides the small TGP, three additional single-gene tests were assumed for NSCLC patients (e.g., fragment analysis (HER2/EGFR) to detect larger deletions/insertions, Sanger sequencing (EGFR) and fluorescence in situ hybridisation (ALK, ROS, RET, or MET)) and one single-gene test was assumed for 50% of the melanoma patients (Sanger Sequencing (KIT)). The gene discussed is ERBB2; the disease is melanoma.